Regeneron Pharmaceuticals (REGN) Q2 2019 Earnings Call Transcript
REGN earnings call for the period ending June 30, 2019.
Regeneron Pharmaceuticals
REGN
REGN
$301.31
$3.32
1.1%
BATS BZX Real Time Price as of October 22, 2019, 4:00 p.m. EDT
View Interactive REGN Charts
The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions.
News & Analysis: Regeneron Pharmaceuticals
The Fool has written over 400 articles on Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals Reports Marked Improvement in Q2
Revenue and earnings beat Wall Street estimates thanks to solid growth for Eylea and Dupixent.
3 Top Biotech Stocks to Add to Your Watchlist
It can be tough to pick winners in the world of pharmaceutical development, but Alexion, Regeneron, and Ionis offer investors good chances of strong returns.
The 10 Biggest Biotech Stocks
Here's how these biotech stocks became the biggest on the market -- and how their future prospects look.
Here's Why Regeneron Pharmaceuticals Tumbled 12% in May
Sales growth is slowing, and there's an issue with one of the biotech's pipeline drugs.
Here's the Bad News That Derailed Regeneron's Stock
This big-cap biotech has a problem or two on its hands.
Regeneron Pharmaceuticals (REGN) Q1 2019 Earnings Call Transcript
REGN earnings call for the period ending March 31, 2019.
What's Behind Regeneron's Q1 Revenue and Earnings Misses
The big biotech disappointed investors in the first quarter with slower-than-expected revenue and earnings growth. Here's what you need to know.
Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals
Which stock wins in a battle between these two successful biotechs?
3 Most Profitable Drugmakers in the S&P 500 -- Are They Buys?
These drugmakers' profit margins are sky-high. But does that necessarily mean they're great stocks to buy?
